Abstract:The α-Klotho protein (henceforth denoted Klotho) has antiaging properties, as first observed in mice homozygous for a hypomorphic Klotho gene (kl/kl). These mice have a shortened lifespan, stunted growth, renal disease, hyperphosphatemia, hypercalcemia, vascular calcification, cardiac hypertrophy, hypertension, pulmonary disease, cognitive impairment, multi-organ atrophy and fibrosis. Overexpression of Klotho has opposite effects, extending lifespan. In humans, Klotho levels decline with age, chronic kidney disease, diabetes, Alzheimer's disease and other conditions. Low Klotho levels correlate with an increase in the death rate from all causes. Klotho acts either as an obligate coreceptor for fibroblast growth factor 23 (FGF23), or as a soluble pleiotropic endocrine hormone (s-Klotho). It is mainly produced in the kidneys, but also in the brain, pancreas and other tissues. On renal tubular-cell membranes, it associates with FGF receptors to bind FGF23. Produced in bones, FGF23 regulates renal excretion of phosphate (phosphaturic effect) and vitamin D metabolism. Lack of Klotho or FGF23 results in hyperphosphatemia and hypervitaminosis D. With age, human renal function often deteriorates, lowering Klotho levels. This appears to promote age-related pathology. Remarkably, Klotho inhibits four pathways that have been linked to aging in various ways: Transforming growth factor β (TGF-β), insulin-like growth factor 1 (IGF-1), Wnt and NF-κB. These can induce cellular senescence, apoptosis, inflammation, immune dysfunction, fibrosis and neoplasia. Furthermore, Klotho increases cell-protective antioxidant enzymes through Nrf2 and FoxO. In accord, preclinical Klotho therapy ameliorated renal, cardiovascular, diabetes-related and neurodegenerative diseases, as well as cancer. s-Klotho protein injection was effective, but requires further investigation. Several drugs enhance circulating Klotho levels, and some cross the blood-brain barrier to potentially act in the brain. In clinical trials, increased Klotho was noted with renin-angiotensin system inhibitors (losartan, valsartan), a statin (fluvastatin), mTOR inhibitors (rapamycin, everolimus), vitamin D and pentoxifylline. In preclinical work, antidiabetic drugs (metformin, GLP-1-based, GABA, PPAR-γ agonists) also enhanced Klotho. Several traditional medicines and/or nutraceuticals increased Klotho in rodents, including astaxanthin, curcumin, ginseng, ligustilide and resveratrol. Notably, exercise and sport activity increased Klotho. This review addresses molecular, physiological and therapeutic aspects of Klotho.

Histological Evidence of the Altered Distribution of Osteocytes and Bone Matrix Synthesis in Klotho-Deficient Mice

Relationship of the bone phenotype of the Klotho mutant mouse model of accelerated aging to changes in skeletal architecture that occur with chronological aging

Altered Distribution of Bone Matrix Proteins and Defective Bone Mineralization in Klotho-Deficient Mice

Age-related degradation of mouse cortical bone: implications for the α-klotho gene responsible for bone mechanical integrity in a series of nanoindentation experiments

Premature aging in klotho mutant mice: cause or consequence?

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Klotho deficiency‐induced arterial calcification involves osteoblastic transition of VSMCs and activation of BMP signaling

Mtorc1-Induced Bone Marrow-Derived Mesenchymal Stem Cell Exhaustion Contributes to the Bone Abnormalities in Klotho-Deficient Mice of Premature Aging.

Histochemical Examination on Periodontal Tissues of Klotho-Deficient Mice Fed with Phosphate-Insufficient Diet

Identification of the cleavage sites leading to the shed forms of human and mouse anti-aging and cognition-enhancing protein Klotho

Biological Role of Anti-aging Protein Klotho

Klotho Null Mutation Involvement in Adenosine A2B Receptor-Related Skeletal Muscle Degeneration

Anti‐aging Gene Klotho Deficiency Causes Arterial Calcification via Activating the Bone Morphogenetic Protein Signaling

Cellular Function of Osteocytes in Normal and Αklotho-Deficient Mice

Klotho deficiency causes cardiac ageing by impairing autophagic and activating apoptotic activity

Age-Related Osteoporosis in Biglycan-Deficient Mice is Related to Defects in Bone Marrow Stromal Cells

Age-related matrix stiffening epigenetically regulates α-Klotho expression and compromises chondrocyte integrity

Decreased klotho expression and elevated blood phosphate level in presenilin PS1/PS2 conditional double knockout mice

Differential toxicity profile of secreted and processed α-Klotho expression over mineral metabolism and bone microstructure

Zona Glomerulosa–Derived Klotho Modulates Aldosterone Synthase Expression in Young Female Mice

Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations